Evaluation of Clinical Significance and Feasibility of CT Guided Biopsy of Double Site Lesions:A Preliminary Lung Centered Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 010
- Peking University Third Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with suspected malignancy
- underwent dual site CT guided biopsy in the Third Hospital of Peking University
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy
|
Double site CT guided needle biopsy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
for the combination of two site biopsies
Time Frame: up to 2weeks
|
The incidence of 4 kinds of combined pathological results in different lesion location groups was analyzed.
|
up to 2weeks
|
|
for the combination of two site biopsy approaches 1
Time Frame: up to 2weeks
|
The incidence of pneumothorax on the surgical side after unilateral lung biopsy
|
up to 2weeks
|
|
for the combination of two site biopsy approaches 2
Time Frame: up to 2weeks
|
the incidence of pneumothorax on the surgical side after bilateral lung biopsy
|
up to 2weeks
|
|
for the combination of two site biopsy approaches 3
Time Frame: up to 2weeks
|
the incidence of intra tissue hemorrhage after biopsy were statistically analyzed.
|
up to 2weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huishu Huishu, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M2018060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.